^
Association details:
Biomarker:FAT2 mutation
Cancer:Endometrial Cancer
Drug Class:Immunotherapy
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma

Published date:
08/07/2022
Excerpt:
...the purpose of our study was to explore the role of FAT2 mutations for predicting prognosis and responsiveness to immunotherapy in patients with UCEC….FAT2 mutations suggested better OS (p < 0.001) and disease-free survival (DFS) (p = 0.007) in UCEC.
DOI:
10.1002/cam4.5119